Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy-Reference-Cited by-同舟云学术

Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy

Published:2017-01-24 Issue:1 Volume:2017 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Bell Jennifer M¹,Shields Michael D¹,Watters Janet²,Hamilton Alistair³,Beringer Timothy⁴,Elliott Mark⁵,Quinlivan Rosaline⁶,Tirupathi Sandya⁷,Blackwood Bronagh¹

Affiliation:

1. Queen's University Belfast; Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences; Room 02.041, 2nd Floor Mulhouse, Grosvenor Road Belfast Northern Ireland UK BT12 6BJ

2. Belfast Health and Social Care Trust; GP Out of Hours Service; Belfast Northern Ireland UK

3. Belfast Health and Social Care Trust; Withers Orthopaedic Centre; Musgrave Park Hospital, Royal Group of Hospitals, Stockman's Lane Belfast Northern Ireland UK

4. Belfast Health and Social Care Trust; Department of Care for the Eldery; Florence Elliot Centre Royal Victoria Hospital Belfast Northern Ireland UK BT12 6BA

5. Musgrave Park Hospital, Belfast Health and Social Care Trust; Belfast UK

6. UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery and Great Ormond Street; MRC Centre for Neuromuscular Diseases and Dubowitz Neuromuscular Centre; PO Box 114 London UK WC1B 3BN

7. Royal Belfast Hospital for Sick Children; Paediatric Neurology; 180 Falls Road Belfast UK BT12 6BE

Publisher

Wiley

Subject

Pharmacology (medical)

Reference248 articles.

1. Effects of low-magnitude high-frequency vibration on bone density, bone resorption and muscular strength in ambulant children affected by Duchenne muscular dystrophy;Bianchi;Journal of Bone and Mineral Research,2013

2. EudraCT2009-017649-67 Bone health in Duchenne muscular dystrophy - a case controlled study of risedronate use www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-017649-67

3. Risedronate use in Duchenne muscular dystrophy: a pilot randomised control trial;McSweeney;Hormone Research in Paediatrics,2014

4. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial;Adachi;Arthritis & Rheumatism,2001

5. Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment;Bianchi;Osteoporosis International,2011

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy;Osteoporosis International;2024-01-26

2. 269th ENMC international workshop: 10 years of clinical trials in Duchenne muscular dystrophy – What have we learned? 9–11 December 2022, Hoofddorp, The Netherlands;Neuromuscular Disorders;2023-11

3. Frailty and the Interactions between Skeletal Muscle, Bone, and Adipose Tissue-Impact on Cardiovascular Disease and Possible Therapeutic Measures;International Journal of Molecular Sciences;2023-02-25

4. A Scoping Review of the Recent Clinical Practice Regarding the Evaluation of Bone Mineral Density in Children and Adolescents with Neuromuscular Diseases;Medicina;2023-02-08

5. Update of the Brazilian consensus recommendations on Duchenne muscular dystrophy;Arquivos de Neuro-Psiquiatria;2023-01